Comorbidity of depression and panic disorder

Journal of Clinical Psychiatry

Volumn 57, Issue SUPPL. 10, 1996, Pages 34-44

  Gorman, Jack M ^a   Coplan, Jeremy D ^a  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ALPRAZOLAM; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; CARBON DIOXIDE; CHLORDIAZEPOXIDE; CLONIDINE; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; DEXAMETHASONE; FENFLURAMINE; FLUOXETINE; GROWTH HORMONE; HYDROCORTISONE; IMIPRAMINE; LACTIC ACID; MONOAMINE OXIDASE INHIBITOR; PAROXETINE; PROTIRELIN; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; YOHIMBINE;

ANXIETY NEUROSIS; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE COURSE; HORMONE RESPONSE; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INHALATIONAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MORBIDITY; NONHUMAN; ORAL DRUG ADMINISTRATION; PANIC; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PSYCHIATRIC DIAGNOSIS; PSYCHOTHERAPY; SEROTONINERGIC TRANSMISSION; SUICIDE ATTEMPT; TREATMENT OUTCOME;

ADULT; CLONIDINE; COMORBIDITY; DEPRESSIVE DISORDER; HUMAN GROWTH HORMONE; HUMANS; PANIC DISORDER; PROGNOSIS; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN; SUICIDE, ATTEMPTED; TERMINOLOGY; TREATMENT OUTCOME;

EID: 0029851758     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (63)

1. Lydiard RB. Coexisting depression and anxiety: special diagnostic and treatment issues. J Clin Psychiatry 1991;52(6, suppl):48-54
2. Klerman GL. Depression and panic anxiety: the effect of depressive comorbidity on response to drug treatment of patients with panic disorder and agoraphobia. J Psychiatr Res 1990;24(suppl 2):27-41
3. Regier DA, Boyd JH, Burke JD Jr, et al. One-month prevalence of mental disorders in the United States. Arch Gen Psychiatry 1988;45:977-986
4. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 1994;51:8-19
5. Keller MB, Baker LA. The clinical course of panic disorder and depression. J Clin Psychiatry 1992;53(3, suppl):5-8
6. Hamilton M. Frequency of symptoms in melancholia (depressive illness). Br J Psychiatry 1989;154:201-206
7. Fawcett J, Kravitz HM. Anxiety syndromes and their relationship to depressive illness. J Clin Psychiatry 1983;44(8, sec 2):8-11
8. Halle MT, Dilsaver SC. Comorbid panic disorder in patients with winter depression. Am J Psychiatry 1993;150:1108-1110
9. Chen Y-W, Dilsaver SC. Comorbidity of panic disorder in bipolar illness: evidence from the Epidemiologic Catchment Area survey. Am J Psychiatry 1995;152:280-282
10. Stein MB, Tancer ME, Uhde TW. Major depression in patients with panic disorder: factors associated with course and recurrence. J Affect Disord 1990;19:287-296
11. Kahn RJ, McNair DM, Lipman RS, et al. Imipramine and chlordiazepoxide in depressive and anxiety disorders, II: efficacy in anxious outpatients. Arch Gen Psychiatry 1986;43:79-85
12. Stavrakaki C, Vargo B. The relationship of anxiety and depression: a review of the literature. Br J Psychiatry 1986;149:7-16
13. Coryell W, Endicott J, Andreasen NC, et al. Depression and panic attacks: the significance of overlap as reflected in follow-up and family study data. Am J Psychiatry 1988;145:293-300
14. Louie AK, Lewis TB, Lannon RA. Use of low-dose fluoxetine in major depression and panic disorder. J Clin Psychiatry 1993;54:435-438
15. Grunhaus L, Rabin D, Greden JF. Simultaneous panic and depressive disorder: response to antidepressant treatments. J Clin Psychiatry 1986;47: 4-7
16. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1987:724-725
17. World Health Organization. The ICD-10 Classification of Mental and Behavioral Disorders. Geneva, Switzerland: World Health Organization; 1992
18. Markowitz J, Weissman MM, Ouellette R, et al. Panic disorder and quality of life. Arch Gen Psychiatry 1989;46:984-992
19. Weissman MM, Klerman GL, Markowitz JS, et al. Suicidal ideation and suicide attempts in panic disorder and attacks. N Engl J Med 1989;321: 1209-1214
20. Johnson J, Weissman MM, Klerman GL. Panic disorder, comorbidity, and suicide attempts. Arch Gen Psychiatry 1990;47:805-808
21. Nofzinger EA, Buysse DJ, Reynolds CF III, et al. Sleep disorders related to another mental disorder (nonsubstance/primary): a DSM-IV literature review. J Clin Psychiatry 1993:54:244-255
22. Loosen PT, Prange AJ Jr. Serum thyrotropin response to thyrotropin-releasing hormone in psychiatric patients: a review. Am J Psychiatry 1982;139: 405-416
23. 2-adrenergic agonist clonidine. Biol Psychiatry 1984;19:131-156
24. Charney DS, Heninger GR, Sternberg DE, et al. Adrenergic receptor sensitivity in depression: effects of clonidine in depressed patients and healthy patients. Arch Gen Psychiatry 1982;39:290-294
25. Stokes PE, Pick GR, Stoll PM, et al. Pituitary-adrenal function in depressed patients: resistance to dexamethasone suppression. J Psychiatr Res 1975; 12:271-281
26. Gibbons JL, McHugh PR. Plasma cortisol in depressive illness. J Psychiatr Res 1962;1:162-171
27. Uhde TW, Roy-Byrne P, Gillin JC, et al. The sleep of patients with panic disorder: a preliminary report. Psychiatry Res 1984;12:251-259
28. Stein MB, Uhde TW. Endocrine, cardiovascular, and behavioral effects of intravenous protirelin in patients with panic disorder. Arch Gen Psychiatry 1991;48:148-156
29. Uhde TW, Vittone BJ, Siever LJ, et al. Blunted growth hormone response to clonidine in panic disorder patients. Biol Psychiatry 1986;21:1077-1081
30. Charney DS, Heninger GR. Abnormal regulation of noradrenergic function in panic disorder. Arch Gen Psychiatry 1986;43:1042-1054
31. Curtis G, Lee MA, Glitz DA, et al. Growth hormone response to clonidine in anxiety disorders. Biol Psychiatry 1989;25:6A
32. Coplan JD, Papp LA, Martinez J, et al. Persistence of blunted human growth hormone response to clonidine in fluoxetine-treated patients with panic disorder. Am J Psychiatry 1995;152:619-622
33. Asberg M, Bertilsson L, Martensson B, et al. CSF monoamine metabolites in melancholia. Acta Psychiatr Scand 1984;69:201-219
34. Coppen AJ, Doonan DP. Serotonin and its place in the pathogenesis of depression. J Clin Psychiatry 1988:49(8, suppl):4-11
35. Sarrias MJ, Artigas F, Martinez E, et al. Decreased plasma serotonin in melancholic patients: a study with clomipramine. Biol Psychiatry 1987;22: 1429-1438
36. 2 and β-adrenergic receptor binding in the frontal cortices of suicide victims. Arch Gen Psychiatry 1986;43:954-959
37. 2 and β-adrenergic receptor binding sites in the brain of suicide victims. Arch Gen Psychiatry 1990;47:1038-1047
38. Schneier FR, Liebowitz MR, Davies SO, et al. Fluoxetine in panic disorder. J Clin Psychopharmacol 1990;10:119-121
39. Oehrberg S, Christiansen PE, Behnke K. Paroxetine in the treatment of panic disorder: a randomized, double blind, placebo controlled study. Br J Psychiatry 1995;167:374-379
40. Targum SD, Marshall LE. Fenfluramine provocation of anxiety in patients with panic disorder. Psychiatry Res 1989;28:295-306
41. Targum SD. Differential responses to anxiogenic challenge studies in patients with major depressive disorder and panic disorder. Biol Psychiatry 1990;28:21-34
42. Norman TR, Judd FK, Gregory M, et al. Platelet serotonin uptake in panic disorder. J Affect Disord 1986;11:69-72
43. Kent JM, Martinez J, Papp LA, et al. Carbon dioxide sensitivity following tryptophan depletion in patients with panic disorder. In: New Research Program and Abstracts of the 147th annual meeting of the American Psychiatric Association; May 23, 1994; Washington, DC. Abstract NR88:77
44. Papp LA, Klein DF, Gorman JM. Carbon dioxide hypersensitivity, hyperventilation, and panic disorder. Am J Psychiatry 1993;150: 1149-1157
45. Rose RM, Jenkins CD, Hurst M, et al. Endocrine activity in air traffic controllers at work, I: characterization of cortisol and growth hormone levels during the day. Psychoneuroendocrinology 1982;7:101-111
46. Woods SW, Charney DS, McPherson CA, et al. Situational panic attacks: behavioral, physiologic, and biochemical characterization. Arch Gen Psychiatry 1987;44:365-375
47. 2 in healthy subjects and panic anxiety patients before and after alprazolam treatment. Arch Gen Psychiatry 1986;43:900-909
48. Liebowitz MR, Gorman JM, Fyer AJ, et al. Lactate provocation of panic attacks, II: biochemical and psychological findings. Arch Gen Psychiatry 1985;42:709-719
49. Carr DB, Sheehan DV, Surman OS, et al. Neuroendocrine correlates of lactate-induced anxiety and their response to chronic alprazolam therapy. Am J Psychiatry 1986;143:483-494
50. Hollander E, Liebowitz MR, Cohen B, et al. Cortisol as a predictor of sodium lactate induced panic. Arch Gen Psychiatry 1989;46:135-140
51. Coplan J, Pine D, Goetz R, et al. Monoamine and HPA function in panic: clinical and preclinical approaches. Neuropsychopharmacology 1994;10 (35):91-95
52. Roy-Byrne PP, Uhde TW, Post RM, et al. The corticotropin-releasing hormone stimulation test in patients with panic disorder. Am J Psychiatry 1986;143:896-899
53. Gold PW, Loriaux DL, Roy A, et al. Responses to corticotropin-releasing hormone in the hypercortisolism of depression and Cushing's disease: pathophysiologic and diagnostic implications. N Engl J Med 1986;314: 1329-1335
54. Carroll BJ, Feinberg M, Greden JF, et al. A specific laboratory test for the diagnosis of melancholia: standardization, validation, and clinical utility. Arch Gen Psychiatry 1981;38:15-22
55. Coryell W, Noyes R Jr, Reich J. The prognostic significance of HPA-axis disturbance in panic disorder: a three-year follow-up. Biol Psychiatry 1991;29:96-102
56. Rosenblum LA, Coplan JD, Friedman S, et al. Adverse early experiences affect noradrenergic and serotonergic functioning in adult primates. Biol Psychiatry 1994;35:221-227
57. Coplan JD, Andrews MA, Rosenblum LA, et al. Persistent elevations of cerebrospinal fluid concentrations of corticotropin-releasing factor in grown non-human primates exposed to early life stressors: implications for the pathophysiology of mood and anxiety disorders. Proc Natl Acad Sci U S A. In press
58. Rosenbaum JF, Biederman J, Gersten M, et al. Behavioral inhibition in children of parents with panic disorder and agoraphobia: a controlled study. Arch Gen Psychiatry 1988;45:463-470
59. Kagan J, Reznick J, Clarke C, et al. Behavioral inhibition to the unfamiliar. Child Dev 1984;55:2215-2225
60. VanValkenburg C, Akiskal HS, Puzantian V, et al. Anxious depressions: clinical, family history, and naturalistic outcome - comparisons with panic and major depressive disorders. J Affect Disord 1984;6:67-82
61. Keller MB, Lavori PW, Goldenberg IM, et al. Influence of depression on the treatment of panic disorder with imipramine, alprazolam and placebo. J Affect Disord 1993;28:27-38
62. Lesser IM, Rubin RT, Pecknold JC, et al. Secondary depression in panic disorder and agoraphobia. Arch Gen Psychiatry 1988;45:437-443
63. Maddock RJ, Blacker KH. Response to treatment in panic disorder with associated depression. Psychopathology 1991;24:1-6